RO-3306 is a selective inhibitor of CDK1 (IC50 = 35 nM versus CDK2 IC50 = 340nM).1,2 It induces G2/M phase cell cycle arrest and apoptosis. Inhibition of CDK1 with RO-3306 has been shown to have synergistic effects with PARP inhibitors in treating various breast cancers.3,4 It has also been demonstrated to overcome apoptotic resistance in BRAFV600E human colorectal cancer cells.5
* VAT and and shipping costs not included. Errors and price changes excepted
